ImageneBio Inc
NASDAQ:IMABiotechnology
+$0.35 today
- Market cap
- $52.00M
- Beta
- 0.72
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.02
Volume 0.00M
Average 0.35M
IMA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
ImageneBio IncNASDAQ: IMA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $876K fell 3.1% year over year, ahead of the -67.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 1617.6% from the prior quarter. Over 3 fiscal years it compounded at +26.9% a year.
Context
- Stock-based compensation amounted to 1923.9% of revenue in FY2025, up 1772.6 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -3.1% holds above the trailing-twelve-month pace of -67.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 15.39M USD
- Year-over-year change
- +190.7%
- 4-year CAGR
- +31.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.39M | +190.7% |
| FY2024 | 2024-12-31 | 5.3M | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 7.53M | +45.4% |
| FY2021 | 2021-12-31 | 5.18M | — |
Stock-Based Compensation vs competitors
How IMA compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -67.0% is the 7th highest of 8, against a peer median of -16.6%.
- Over three fiscal years its annual growth of +26.9% compares with a peer median of +1.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.03M USD | -58.5% | -18.9% | 10.1% | |
| LTM Mar 2026 | $7.69M USD | -12.5% | +2.7% | 768.9% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $6.36M USD | -16.6% | +1.2% | — |
| FY2025 | $3.73M USD | -44.6% | +54.6% | 5821.9% | |
| LTM Mar 2026 | €2.48M EUR | -152.9% | — | 8455.2% | |
| LTM Mar 2026 | $2.41M USD | -6.9% | -9.8% | 33.9% | |
| LTM Mar 2026 | $1.45M USD | +61.5% | +10.9% | — | |
IMAImageneBio Inc | LTM Mar 2026 | $1.39M USD | -67.0% | +26.9% | — |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $638K USD | — | — | — |
| Peer median (excluding IMA) | — | -16.6% | +1.9% | 768.9% | |
Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (34.12M) | (68.77M) | (68.17M) | (49.23M) | (52.4M) |
| Depreciation & Amortization | 544K | 751K | 1.02M | 490K | 328K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.18M | 7.53M | 0 | 5.3M | 15.39M |
| Change in Working Capital | (33.03M) | (15.14M) | (21.67M) | (3.98M) | (19.19M) |
| Accounts Receivables | 361K | (291K) | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | (2.87M) | (1.17M) | (2.82M) |
| Other Working Capital | (33.39M) | (14.85M) | (18.8M) | (2.81M) | (16.37M) |
| Other Non-Cash Items | 1.17M | 1.52M | 9.07M | 1.42M | 8.02M |
| Operating Cash Flow | (60.25M) | (74.11M) | (79.74M) | (46M) | (47.84M) |
| Capital Expenditures | (1.76M) | (1.43M) | (414K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (5.22M) |
| Purchases of Investments | 0 | (216.34M) | (90.05M) | (88.3M) | (10.4M) |
| Sales of Investments | 0 | 118.49M | 154.61M | 60.46M | 9.8M |
| Other Investing Activities | 0 | 0 | 0 | (7.07M) | 0 |
| Investing Cash Flow | (1.76M) | (99.28M) | 64.14M | (34.9M) | (5.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 15M |
| Common Stock Issued | 131.3M | 0 | 37.56M | 0 | 65.84M |
| Common Stock Repurchased | 0 | 0 | (663K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 582K | 1.1M | 39.09M | 0 | 54.63M |
| Financing Cash Flow | 131.74M | 1.1M | 75.98M | 0 | 135.47M |
| Effect of Forex Changes | 0 | 0 | (406K) | 0 | 604K |
| Net Change in Cash | 69.73M | (172.3M) | 59.98M | (80.91M) | 82.41M |
| Free Cash Flow | (62.01M) | (75.54M) | (80.16M) | (46M) | (47.84M) |
ImageneBio Inc
NASDAQ:IMA
Intrinsic Alpha fair value
Locked
Current Price
$4.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.